Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Shenqi Sherong Pill · 1 trial · 1 indication
Change in Modified Japanese Orthopaedic Association (mJOA) score (on a scale from 0 to 18, with lower scores indicating greater disability) from baseline at Day 42 after administration; the mJOA which is a clinician administered scale to evaluate four clinical dimensions; motor dysfunction score for upper and lower extremities, sensation loss and sphincter dysfunction.
| Arm | Type | Description |
|---|---|---|
| Shenqi Sherong Pill | EXPERIMENTAL | 6g per bag |
| Placebo | PLACEBO_COMPARATOR | 6g per bag |
| Name | Type | Description |
|---|---|---|
| Shenqi Sherong Pill | DRUG | two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks |
| Placebo | DRUG | two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks |
Inclusion Criteria: Participants can only be selected if they meet all the inclusion criteria 1. Age 18-75 years old (including 18 and 75 years old), gender unlimited; 2. Accord with Western medicine diagnosis standards of Cervical Spondylotic Myelopathy; 3. Accord with Chinese medicine diagnosis ...
Shenqi Sherong Pill is an investigational small molecule being studied for the treatment of Cervical Spondylotic Myelopathy, a condition affecting the spinal cord in the neck. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Shenqi Sherong Pill is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting clinical trials to evaluate the drug's efficacy and safety for Cervical Spondylotic Myelopathy.
Shenqi Sherong Pill is in Phase 3 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 3 trial has been completed to assess its efficacy and safety in patients with Cervical Spondylotic Myelopathy.
Shenqi Sherong Pill has one completed Phase 3 clinical trial registered as NCT06377072. The trial enrolled 428 participants with Cervical Spondylotic Myelopathy in China and was a randomized, double-blind, placebo-controlled study. It included adults aged 18 years and older.
Shenqi Sherong Pill is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for Cervical Spondylotic Myelopathy. The completed Phase 3 trial was conducted in China, and regulatory approval has not been granted.